Drug
Donafenib clinical trials
Includes 6 studies of Donafenib tosylate.
- studies test it
- 41
- open now
- 14
- in phase 3
- 3
- first study started
- 2014
Keep track of what changes. Save the donafenib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Combined with it in one product
Studies by the year they started
41 studies that test it; most in 2021 (9)
| Year | Studies |
|---|---|
| 2014 | 2 |
| 2015 | 1 |
| 2016 | 4 |
| 2017 | 1 |
| 2018 | 3 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 9 |
| 2022 | 3 |
| 2023 | 1 |
| 2024 | 9 |
| 2025 | 1 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 12
- Phase 2
- 29
- Phase 3
- 3
- Phase 4
- 3
- No phase
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 15 · Other 26
Suzhou Zelgen Biopharmaceuticals Co.,Ltd (15) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (3) · Tianjin Medical University Cancer Institute and Hospital (3) · Sun Yat-sen University (2) · Fudan University (2) · Anhui Provincial Hospital (2) · Second Affiliated Hospital of Guangzhou Medical University (1) · Shanghai Zhongshan Hospital (1)
Often tested with
Tested in the same studies.
Sintilimab (6) · Tislelizumab (3) · Toripalimab (3) · Lenvatinib (2) · Apatinib (2) · Immune Checkpoint Inhibitors (1) · Epalrestat (1) · Camrelizumab (1)
Studies
Open first, then newest update. How each study uses donafenib is read from its arms, and is right about nine times in ten.
Testing it · 41
- Epalrestat Combined With HAIC, Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable HCC and DiabetesNot yet recruitingPhase 2Haibo ShaoNCT07557914Written as Donafenib + Tislelizumab
- A Prospective, Single-Arm, Open-Label Clinical Study of the Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Combined With Targeted Therapy and a PD-1 Inhibitor in Patients With Postoperative Hepatocellular Carcinoma and Microvascular InvasionNot yet recruitingPhase 4Zhai WenlongNCT07790419Written as Donafenib + lenvatinib+apatinib
- The DoHAICs Study Expansion PhaseNot yet recruitingPhase 2Tianjin Medical University Cancer Institute and HospitalNCT07584018Written as Donafenib
- FOLFOX-HAIC Combined With Donafenib and Pucotenlimab as First-Line Treatment for Unresectable Intrahepatic CholangiocarcinomaNot yet recruitingPhase 2Sun Yat-sen UniversityNCT07353827Written as Donafenib
- HAIC Combined with Donafenib and Sintilimab As Perioperative Treatment for Resectable Hepatocellular Carcinoma Patients At High Risk of RecurrenceRecruitingPhase 2Fudan UniversityNCT06812039Written as Sintilimab and Donafenib
- Donafenib Combined With Capecitabine for Postoperative Adjuvant Therapy of Biliary Malignant Tumors With High-risk Recurrence RiskRecruitingPhase 2The First Affiliated Hospital with Nanjing Medical UniversityNCT06685289Written as Donafenib
- Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid CancerRecruitingPhase 2West China HospitalNCT06482086Written as Donafenib
- Donafenib as Adjuvant Therapy Following Ablation for Recurrent HCCRecruitingNot applicableSun Yat-sen UniversityNCT06609876Written as Donafenib
- TIPS Plus Half-dose Donafenib in AHCC with PVTT-associated Portal HypertensionRecruitingPhase 2Fei GaoNCT06646198Written as Donafenib
- Postoperative Adjuvant Therapy of Donafenib for Hepatocellular CarcinomaRecruitingNot applicableSun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT06581315Written as Donafenib
- Donafenib Combine With Sintilimab and HAIC in Neoadjuvant of Resectable Hepatocellular CarcinomaNot yet recruitingPhase 2Tianjin Medical University Cancer Institute and HospitalNCT06512467Written as Donafenib
- Adjuvant Treatment of Patients With High Risk of Recurrent Hepatocellular Carcinoma With Donafenib in Combination With EnvafolimabRecruitingPhase 2Anhui Provincial HospitalNCT06498622Written as Donafenib + Envafolimab
- Donafenib Combined With Immunotherapy and Local Therapy for Unresectable Hepatocellular Carcinoma That Has Failed in Previous TherapyNot yet recruitingPhase 4Tongji HospitalNCT06496815Written as Donafenib
- A Study Evaluating the Efficacy and Safety of ZG005 in Combination With Donafenib or Bevacizumab in Patients With Advanced Hepatocellular CarcinomaNot yet recruitingNot applicableChangsha Taihe HospitalNCT06233994Written as Donafenib Tosilate Tablets
- Hepatic Artery Infusion Chemotherapy Plus Donafenib in Patients With Hepatocellular Carcinoma After SurgeryCompletedPhase 2Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT04962958Written as Donafenib
- A Phase 1/2 Study of Donafenib in Combination With KN046 in Advanced Gastrointestinal TumorsTerminatedPhase 1/2Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT04612712Written as Donafenib Tosilate Tablets
- Donafenib Plus Sintilimab for Advanced HCCCompletedPhase 2Second Affiliated Hospital of Guangzhou Medical UniversityNCT05162352Written as Donafenib+sintilimab
- A Single Center Study of Donafenib Combined With PD-1 + TACE in the First-line Treatment of aHCCCompletedPhase 2Shanghai Zhongshan HospitalNCT05262959Written as Donafenib, PD-1
- A Study of ZG005 Combined With Donafenib in Patients With Advanced Solid TumorStatus unknownPhase 1/2Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT06239298Written as Donafenib Tosilate Tablets
- Donafenib Combined With Hepatic Artery Chemoembolization for Perioperative Treatment of Liver TransplantationStatus unknownPhase 2Beijing Tsinghua Chang Gung HospitalNCT05576909Written as Donafenib
See all 41 studies that test donafenib →
Given in every arm · 3 — donafenib is usual care beside what is tested
- Dapagliflozin Add-on in Unresectable HCC With Metabolic SyndromeNot yet recruitingPhase 2Sun Yat-sen UniversityNCT07729592Written as Donafenib
- Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage HCC: a Multi-center Randomized Controlled Trial.TerminatedPhase 2/3Peking UniversityNCT05171166Written as Donafenib
- Donafenib and Toripalimab Combined With TACE in Patients With Unresectable Hepatocellular CarcinomaActive, not recruitingPhase 1Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT04605185Written as Donafenib Tosilate Tablets
Codes
What other systems call donafenib · ClinicalTrials.gg INT001410
- MeSH (NLM) C000710249donafenibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 41XGO0VS1UDONAFENIBConfirmed FDA, NLM, Wikidata
- Wikidata Q27258473donafenibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C118294DonafenibOne source FDA
- DrugBank DB15414One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000710249 | donafenib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 41XGO0VS1U | DONAFENIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27258473 | donafenib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C118294 | Donafenib | One source FDA |
| DrugBank | DB15414 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.